A5004460743- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Acute Lymphoblastic Leukemia research
- Neutropenia and Cancer Infections
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Renal and related cancers
- Histone Deacetylase Inhibitors Research
- Multiple Myeloma Research and Treatments
- Hematological disorders and diagnostics
- Gut microbiota and health
- Bacteriophages and microbial interactions
- Cholinesterase and Neurodegenerative Diseases
- Gene expression and cancer classification
- COVID-19 and Mental Health
- SARS-CoV-2 and COVID-19 Research
- Quinazolinone synthesis and applications
- Cancer survivorship and care
- Cancer therapeutics and mechanisms
- Heparin-Induced Thrombocytopenia and Thrombosis
- Graphene and Nanomaterials Applications
Heinrich Heine University Düsseldorf
2014-2025
Düsseldorf University Hospital
2014-2025
Integrated Oncology (United States)
2024
Essen University Hospital
2023
Bipar
2021
Abstract The hallmark of multiple myeloma (MM) is a clonal plasma cell infiltration in the bone marrow accompanied by myelosuppression and osteolysis. Premalignant stages such as monoclonal gammopathy undetermined significance (MGUS) asymptomatic smoldering (SMM) can progress to MM. Mesenchymal stromal cells (MSCs) are an integral component microenvironment play important role osteoblast differentiation hematopoietic support. Although alterations have been reported MM contributing...
The development of a fatal, clonal, autonomously proliferating CD4-CD8- chimeric antigen receptor (CAR)+ peripheral T-cell lymphoma (PTCL) occurred 1 month after patient received treatment with tisagenlecleucel for relapsed primary central nervous system lymphoma. PTCL had clonal rearrangement, which was already detectable in the apheresis product CAR manufacturing and 7 months earlier autologous transplantation. Somatic
Mesenchymal stromal cells are involved in the pathogenesis of myelodysplastic syndromes and acute myeloid leukemia, but underlying mechanisms incompletely understood. To further characterize pathological phenotype we performed RNA sequencing mesenchymal from patients with leukemia found a specific molecular signature genes commonly deregulated these disorders. Pathway analysis showed strong enrichment related to osteogenesis, senescence, inflammation inhibitory cytokines, thereby reflecting...
Up to 50% of patients with high-risk myeloid malignancies die relapse after allogeneic stem cell transplantation. Current sequential conditioning regimens like the FLAMSA protocol combine intensive induction therapy TBI or alkylators. Venetoclax has synergistic effects chemotherapy. In a retrospective survey among German transplant centers, we identified 61 that had received FLAMSA-based venetoclax between 2018 and 2022 as an individualized treatment approach. Sixty (98%) active disease at...
As median age of patients with acute myeloid leukemia is 72 years, older continue to be a vulnerable cohort representing significant challenges in clinical practice. Patient-specific comorbidities as well leukemia-specific unfavorable molecular- and cytogenetics confer even poorer outcomes. Treatment AML therefore needs less toxic prevent harm while lowering or eradicating leukemic burden prolong survival. In this retrospective analysis we included 365 from the Düsseldorf registry who were...
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a potentially curative treatment for high-risk hematological malignancies, but early mortality within 100 days remains significant challenge, affecting approximately 18% of patients. Identifying patients critical timely interventions. While static risk scores like the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) and Endothelial Activation Stress (EASIX) are valuable, they do not adapt to patients'...
Positron emission tomography (PET)/computed (CT) imaging is an established tool in diagnosing and staging for various malignancies, however, during immune checkpoint inhibitor (ICI) therapy not only inflammatory changes may mimic disease progression, but also secondary malignancies should be considered the setting of unusual clinical radiographic findings. Here, we present case a 64-year-old man with lymphogenic metastatic malignant melanoma treated ipilimumab/nivolumab, whom PET/CT...
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a key treatment for hematologic malignancies, but donor selection impacts outcomes. In cohort of 152 patients undergoing allo-SCT from 2012 to 2023, haploidentical donors with post-transplant cyclophosphamide (PTCy) showed superior survival compared 9/10 mismatched unrelated (MMUD). Cox regression analysis revealed that not in complete remission (CR) before particularly benefited haplo donors, while those MMUD and lacking CR...
Abstract The gut microbiome is a diverse ecosystem, dominated by bacteria; however, fungi, phages/viruses, archaea, and protozoa are also important members of the microbiota. Exploration taxonomic compositions beyond bacteria as well an understanding interaction between bacteriome with other limited using 16S rDNA sequencing. Here, we developed pipeline enabling simultaneous interrogation (bacteriome, mycobiome, archaeome, eukaryome, DNA virome) antibiotic resistance genes based on optimized...
Azacitidine (Aza) combined with donor lymphocyte infusions (DLI) is an established treatment for relapse of myeloid malignancies after allogeneic transplantation. Based on its immunomodulatory and anti-leukemic properties we considered Lenalidomide (Lena) to act synergistically Aza/DLI improve outcome. We, therefore, prospectively investigated tolerability efficacy this combination as first salvage therapy adults post-transplant acute leukemia, myelodysplastic syndromes chronic...
Few reports suggested a prognostic impact of Wilms'Tumor-1 (WT1)-mRNA overexpression in MDS, but translation into clinical routine was hampered by limited patients numbers, differing sample sources, non-standardized methods/cut-offs. To evaluate whether WT1-mRNA expression yields additional information, we measured peripheral blood (PB) 94 MDS using standardized assay offering validated cut-off to discriminate between normal and overexpression. Overall, 54 (57%) showed overexpression, while...
To provide long-term outcome data and predictors for response survival, we retrospectively analyzed all 151 patients with relapse of myeloid neoplasms after allogeneic hematopoietic stem cell transplantation (allo-HSCT) who were uniformly treated first-line azacitidine (Aza) salvage therapy at our center. Patients molecular (39%) or hematologic (61%), a median 5 cycles Aza least one donor lymphocyte infusion in 70% patients. Overall was 46%, 41% achieving complete (CR) 5% partial remission....
As peripheral blood (PB) Wilm's Tumor 1 (WT1)-mRNA expression is established as MRD-marker during conventional AML chemotherapy, impact of pretransplant WT1 remains unclear. Therefore, we aimed to assess prognostic on post-transplant outcome in patients with AML/MDS.In 64 AML/MDS patients, was retrospectively analyzed using a standardized assay offering high sensitivity, specificity, and validated cut-off. Patients were divided into three groups determined by remission expression....
Intensive treatment protocols for aggressive hematologic malignancies harbor a high risk of serious clinical complications, such as infections. Current techniques monitoring vital signs to detect complications are cumbersome and often fail diagnose them early. Continuous physical activity by means an upper arm medical wearable allowing 24/7 streaming parameters may be promising alternative.This single-arm, single-center observational trial evaluated symptom-related patient-reported outcomes...
Serious clinical complications (SCC; CTCAE grade ≥ 3) occur frequently in patients treated for hematological malignancies. Early diagnosis and treatment of SCC are essential to improve outcomes. Here we report a deep learning model-derived SCC-Score detect predict from time-series data recorded continuously by medical wearable. In this single-arm, single-center, observational cohort study, vital signs physical activity were with wearable 31,234 h 79 (54 Inpatient Cohort (IC)/25 Outpatient...
Patients with acute myeloid leukemia (AML) and nucleophosmin 1 gene mutations (NPM1
Using multi-color flow cytometry analysis, we studied the immunophenotypical differences between leukemic blasts/LSCs from patients with AML/MDS and hematopoietic stem progenitor cells (HSPCs) in complete remission (CR) following their successful treatment. The panel of markers included CD34, CD38, CD45RA, CD123 as representatives for a hierarchical cell (HSPC) classification well programmed death ligand 1 (PD-L1). Rather than restricting evaluation on 2- or 3-dimensional applied...
Acute myeloid leukemia (AML) is characterized by an expansion of leukemic cells and a simultaneous reduction normal hematopoietic precursors in the bone marrow (BM) resulting insufficiency, but underlying mechanisms are poorly understood humans. Assuming that functionally inhibit healthy CD34+ stem progenitor (HSPC) via humoral factors, we exposed BM-derived HSPC to cell-free supernatants derived from AML cell lines as well 24 newly diagnosed patients. Exposure AML-derived significantly...
There is a variety of antineoplastic drugs that are based on natural compounds from ecological niches with high evolutionary pressure. We used two cell lines (Jurkat J16 and Ramos) in screening to assess 300 different naturally occurring regard their activity. The results the 4,6-dibromo-2-(2′,4′-dibromophenoxy)phenol (P01F03), 4,5,6-tribromo-2-(2′,4′-dibromophenoxy)phenol (P01F08), 5-epi-nakijinone Q (P03F03) prompted us perform further research. Using viability apoptosis assays primary...
Little data are available for the expression of immune checkpoint (IC) molecules within myelodysplastic syndrome (MDS). Here, we report increased PD-L1+ CD34+ CD38- and CD38+ stem cell frequencies MDS patients compared to recipients in remission. Additionally, observed exceedingly similar PD1+ Tim-3+ T-cell between acute myeloid leukaemia (AML) samples that were elevated Furthermore, found highly dynamic serial relapsing with excess blasts (MDS-EB II) patients, correlating further disease...
Somatic mutations and pretransplant strategy both impact the outcome of patients with myelodysplastic syndromes (MDS), acute myeloid leukemia derived from MDS (sAML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). While prognostic influence several somatic mutations, especially TP53, as a disease-related variable is established,1 optimal less well defined due to lack prospective trials. In recent analysis we showed that direct, so called upfront at least not inferior...
Up to 50% of patients with high-risk myeloid malignancies die relapse after allogeneic stem cell transplantation. Current sequential conditioning regimens like the FLAMSA protocol combine intensive induction therapy TBI or alkylators. Venetoclax has synergistic effects chemotherapy. In a retrospective survey among German transplant centers, we identified 61 that had received based between 2018 and 2022 as an individualized treatment approach. Sixty (98%) active disease at 74% genetic...